story of the week
First-Line Avelumab Plus Axitinib vs Sunitinib in Patients With Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Updated Efficacy Results From the JAVELIN Renal 101 Trial: First-Line Avelumab Plus Axitinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma
Ann. Oncol 2020 Apr 24;[EPub Ahead of Print], TK Choueiri, RJ Motzer, BI Rini, J Haanen, MT Campbell, B Venugopal, C Kollmannsberger, G Gravis-Mescam, M Uemura, JL Lee, MO Grimm, H Gurney, M Schmidinger, J Larkin, MB Atkins, SK Pal, J Wang, M Mariani, S Krishnaswami, P Cislo, A Chudnovsky, C Fowst, B Huang, A di Pietro, L AlbigesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.